Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$35.07

-0.01 (-0.03%)

08:29
01/19/18
01/19
08:29
01/19/18
08:29

AstraZeneca reports Fasenra receives approval in Japan

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the Japanese Ministry of Health, Labor and Welfare has approved Fasenra as an add-on treatment for bronchial asthma in patients who continue to experience asthma exacerbations despite treatment with high-dose inhaled corticosteroid and other asthma controllers. The Japanese approval follows US FDA approval in November 2017 and European Commission marketing authorization in January 2018. Interactions with regulatory authorities in the rest of the world are ongoing, the company noted.

  • 25

    Jan

  • 08

    Feb

  • 08

    Mar

  • 23

    Apr

AZN AstraZeneca
$35.07

-0.01 (-0.03%)

12/05/17
DBAB
12/05/17
NO CHANGE
DBAB
Buy
AstraZeneca positioned to lead in ovarian cancer, says Deutsche Bank
Deutsche Bank analyst Richard Parkes believes recent "strong data" of Tagrisso/Imfinzi mark a turning point for AstraZeneca and the profitability of its lung cancer franchise. The analyst says his survey of 47 U.S. physicians treating patients with ovarian cancer suggests "strong uptake" of the PARP inhibitors class across multiple lines of therapy. Physicians perceive the various approved drugs as comparable on efficacy but with tolerability favoring AstraZeneca's Lynparza, Parkes tells investors in a research note. He believes AstraZeneca will emerge as market leader in a potential greater than $7B class, with "significant upside potential" to consensus forecasts. The analyst reiterates a Buy rating on the shares.
12/29/17
JPMS
12/29/17
UPGRADE
JPMS
Overweight
AstraZeneca upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Gordon upgraded AstraZeneca to Overweight and raised his price target for the shares to 55 pounds from 48 pounds. The company's "superior medium-term growth outlook," which is twice the peer average, warrants a 25% sector premium, Gordon tells investors in a research note. He believes downside risk around the Mystic trial failure and "overly high base business expectations" have now lessened with consensus earnings forecasts declining 15%. The analyst expects AstraZeneca to return to sales growth in 2018, even without further immuno-oncology trial success. Astra has 10 Phase III readouts, with fairly low expectations across the board, Gordon argues.
12/29/17
12/29/17
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. AstraZeneca (AZN) upgraded to Overweight from Neutral at JPMorgan with analyst James Gordon saying the company's "superior medium-term growth outlook," which is twice the peer average, warrants a 25% sector premium. 2. PriceSmart (PSMT) upgraded to Outperform from Market Perform at IFS Securities. 3. Novo Nordisk (NVO) upgraded to Neutral from Underweight at JPMorgan with analyst Richard Vosser saying he expects "strong" oral semaglutide Phase III newsflow in 2018. 4. Syntel (SYNT) downgraded to Underperform from Market Perform at Wells Fargo with analyst Ed Caso saying he sees the company's "weak" positioning for the ongoing shift in information technology demand from "legacy" low-cost offshore-centric software services to more onshore-necessary "digital" solutions as dragging down its growth and margins. 5. RioCan REIT downgraded to Sector Perform from Outperform at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/02/18
ADAM
01/02/18
NO CHANGE
Target $77
ADAM
Buy
ANI Pharmaceuticals best positioned in emerging generics space, says Canaccord
Canaccord analyst Dewey Steadman said ANI Pharmaceuticals (ANIP) is one of the best positioned names in the emerging generics space. He noted the company has a basket of additional branded tail assets from its AstraZeneca (AZN) acquisitions, additional cash on hand and credit facilities for future transactions, and a solid core business. Steadman reiterated his Buy rating and raised his price target to $77 from $75 on ANI Pharmaceuticals shares.

TODAY'S FREE FLY STORIES

HCSG

Healthcare Services

$42.38

-0.3297 (-0.77%)

, GEN

Genesis Healthcare

$1.45

-0.09 (-5.84%)

08:27
07/18/18
07/18
08:27
07/18/18
08:27
Recommendations
Healthcare Services, Genesis Healthcare analyst commentary  »

Benchmark would be buyers…

HCSG

Healthcare Services

$42.38

-0.3297 (-0.77%)

GEN

Genesis Healthcare

$1.45

-0.09 (-5.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 05

    Oct

FPI

Farmland Partners

$6.28

0.185 (3.04%)

08:26
07/18/18
07/18
08:26
07/18/18
08:26
Upgrade
Farmland Partners rating change  »

Farmland Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIC

Ericsson

$7.64

-0.015 (-0.20%)

08:25
07/18/18
07/18
08:25
07/18/18
08:25
Earnings
Ericsson reports Q2 non-IFRS EPS SEK(9) vs. SEK33 last year »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOG

GasLog

$17.10

(0.00%)

, GLNG

Golar LNG

$27.06

0.11 (0.41%)

08:23
07/18/18
07/18
08:23
07/18/18
08:23
Initiation
GasLog, Golar LNG, GasLog Partners, Golar LNG Partners, Hoegh LNG initiated  »

GasLog, GolarLNG…

GLOG

GasLog

$17.10

(0.00%)

GLNG

Golar LNG

$27.06

0.11 (0.41%)

GLOP

GasLog Partners

$23.40

0.05 (0.21%)

GMLP

Golar LNG Partners

$14.71

-0.09 (-0.61%)

HMLP

Hoegh LNG

$17.90

0.3 (1.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 01

    Oct

CMA

Comerica

$91.84

1.15 (1.27%)

, BBT

BB&T

$51.99

0.37 (0.72%)

08:22
07/18/18
07/18
08:22
07/18/18
08:22
Recommendations
Comerica, BB&T, U.S. Bancorp analyst commentary  »

Comerica could be viewed…

CMA

Comerica

$91.84

1.15 (1.27%)

BBT

BB&T

$51.99

0.37 (0.72%)

USB

U.S. Bancorp

$51.29

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 19

    Jul

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:20
07/18/18
07/18
08:20
07/18/18
08:20
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

$0.00

(0.00%)

08:20
07/18/18
07/18
08:20
07/18/18
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:20
07/18/18
07/18
08:20
07/18/18
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDP

Keurig Dr Pepper

$24.97

0.2 (0.81%)

08:20
07/18/18
07/18
08:20
07/18/18
08:20
Initiation
Keurig Dr Pepper initiated  »

Keurig Dr Pepper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$188.40

0.48 (0.26%)

08:20
07/18/18
07/18
08:20
07/18/18
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$72.90

0.54 (0.75%)

08:19
07/18/18
07/18
08:19
07/18/18
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$75.10

-0.26 (-0.35%)

08:19
07/18/18
07/18
08:19
07/18/18
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$112.97

0.12 (0.11%)

08:19
07/18/18
07/18
08:19
07/18/18
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$58.88

0.76 (1.31%)

08:19
07/18/18
07/18
08:19
07/18/18
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$52.45

-0.03 (-0.06%)

08:18
07/18/18
07/18
08:18
07/18/18
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$52.92

0.44 (0.84%)

08:18
07/18/18
07/18
08:18
07/18/18
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$87.34

0.49 (0.56%)

08:18
07/18/18
07/18
08:18
07/18/18
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$167.51

0.75 (0.45%)

08:17
07/18/18
07/18
08:17
07/18/18
08:17
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$251.26

0.64 (0.26%)

08:17
07/18/18
07/18
08:17
07/18/18
08:17
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$280.42

1.04 (0.37%)

08:17
07/18/18
07/18
08:17
07/18/18
08:17
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$27.49

0.04 (0.15%)

08:17
07/18/18
07/18
08:17
07/18/18
08:17
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMH

Market Vectors Semiconductor

$106.04

1.39 (1.33%)

08:16
07/18/18
07/18
08:16
07/18/18
08:16
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXR

Extra Space Storage

$94.67

-2.05 (-2.12%)

08:16
07/18/18
07/18
08:16
07/18/18
08:16
Downgrade
Extra Space Storage rating change  »

Extra Space Storage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

QQQ

Invesco QQQ Trust

$180.29

1.11 (0.62%)

08:16
07/18/18
07/18
08:16
07/18/18
08:16
Technical Analysis
Invesco QQQ Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$COMP

Nasdaq Composite

$0.00

(0.00%)

08:16
07/18/18
07/18
08:16
07/18/18
08:16
Technical Analysis
Nasdaq Composite: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.